Pharsight

1. List of Oxaydo drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7510726	ZYLA	Methods and compositions for deterring abuse of opioid containing dosage forms	Nov, 2023 (5 months from now)
US7981439	ZYLA	Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof	Nov, 2023 (5 months from now)
US8409616	ZYLA	Extended release opioid abuse deterrent compositions and methods of making same	Nov, 2023 (5 months from now)
US8637540	ZYLA	Compositions for deterring abuse of opioid containing dosage forms	Nov, 2023 (5 months from now)
US9492443	ZYLA	Abuse deterrent compositions and methods of making same	May, 2024 (11 months from now)
US7201920	ZYLA	Methods and compositions for deterring abuse of opioid containing dosage forms	Mar, 2025 (1 year, 9 months from now)

Do you want to check out OXAYDO patents from before 2022?

Market Authorisation Date: 17 June, 2011

Treatment: NA

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
5 mg and 7.5 mg	07 Feb, 2012	1		16 Mar, 2025	Extinguished

Strength	Dosage	Availability
5MG	TABLET;ORAL	Prescription
7.5MG	TABLET;ORAL	Prescription

OXAYDO family patents

United States

Australia

European Union

Israel

Spain

Canada

2. List of Oxycontin drug patents

Application	Filing Date	Opposition Party	Legal Status
EP06706682A	2017-12-19	G. L. Pharma GmbH	Revoked
EP11186168A	2016-10-11	James Poole Limited	Opposition rejected
EP10011792A	2015-10-28	Setna, Rohan P.	Granted and Under Opposition
EP10011792A	2015-10-28	Hoffmann Eitle	Granted and Under Opposition
EP10011792A	2015-10-27	James Poole Limited	Granted and Under Opposition
EP10011792A	2015-10-26	Acino Pharma AG	Granted and Under Opposition
EP05730345A	2011-12-09	Actavis group PTC ehf	Patent maintained as amended
EP05730345A	2011-12-08	Acino Pharma AG	Patent maintained as amended
EP05730345A	2011-12-05	Elend, Almut Susanne	Patent maintained as amended
EP2005006983W	2009-10-13	Sanofi-Aventis Deutschland GmbH	Patent maintained as amended
EP2005006983W	2009-10-13	Ypsomed AG	Patent maintained as amended
EP04763833A	2008-03-27	Purdue Pharma LP	Opposition rejected
EP04763834A	2007-12-14	Purdue Pharma LP	Opposition rejected

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US9492393	February, 2018	Terminated-Settled	Purdue Pharma L.P.	Kashiv Pharma, LLC
US9492392	February, 2018	Terminated-Settled	Purdue Pharma L.P.	Kashiv Pharma, LLC

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10696684	PURDUE PHARMA LP	Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone	Mar, 2025 (1 year, 9 months from now)
US10407434	PURDUE PHARMA LP	Process for preparing oxycodone compositions	Mar, 2025 (1 year, 9 months from now)
US9522919	PURDUE PHARMA LP	Oxycodone compositions	Mar, 2025 (1 year, 9 months from now)
US9073933	PURDUE PHARMA LP	Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone	Mar, 2025 (1 year, 9 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9675610	PURDUE PHARMA LP	Abuse-proofed dosage form	Jun, 2023 (14 days from now)
US10369109	PURDUE PHARMA LP	Abuse-proofed dosage form	Jun, 2023 (14 days from now)
US8309060	PURDUE PHARMA LP	Abuse-proofed dosage form	Nov, 2023 (5 months from now)
US10130591	PURDUE PHARMA LP	Abuse-proofed dosage form	Nov, 2023 (5 months from now)
US10675278	PURDUE PHARMA LP	Crush resistant delayed-release dosage forms	Nov, 2023 (5 months from now)
US11304909	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US8808741	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9492393	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9492391	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9492389	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9492392	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9770416	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9775808	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US8894988	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US9763933	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US11304908	PURDUE PHARMA LP	Tamper resistant dosage forms	Aug, 2027 (4 years from now)
US8894987	PURDUE PHARMA LP	Tamper resistant dosage forms	Mar, 2030 (6 years from now)

Do you want to check out OXYCONTIN patents from before 2022?

Market Authorisation Date: 05 April, 2010

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require ...

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
10MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
15MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
20MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
30MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
40MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
60MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
80MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

OXYCONTIN family patents

180

United States

European Union

Spain

Slovenia

Denmark

Poland

Portugal

Korea, Republic of

Cyprus

Japan

Hong Kong

Croatia

China

Germany

Israel

Argentina

Austria

Peru

Australia

Canada

New Zealand

Brazil

Malaysia

Hungary

Chile

Taiwan

Mexico

South Africa

Russia

Norway

Costa Rica

Ukraine

Singapore

Ecuador

Lithuania

Dominican Republic

Morocco

Guatemala

Jordan

Tunisia

India

Georgia

Finland

Colombia

Saudi Arabia

3. List of Roxybond drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7955619	PROTEGA PHARMS	Abuse resistant drugs, method of use and method of making	Aug, 2028 (5 years from now)
US10314788	PROTEGA PHARMS	Pharmaceutical compositions configured to deter dosage form splitting	Aug, 2028 (5 years from now)